Old Web
English
Sign In
Acemap
>
authorDetail
>
GuangLei Yu
GuangLei Yu
Eli Lilly and Company
Randomized controlled trial
Alopecia areata
Medicine
Hazard ratio
Statistic
3
Papers
9
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
2021
Journal of The American Academy of Dermatology
Brett A. King
Justin M. Ko
Seth Forman
Manabu Ohyama
Natasha Atanaskova Mesinkovska
GuangLei Yu
Jill Shwed McCollam
Margaret Gamalo
Jonathan Janes
Emily Edson-Heredia
Katrin Holzwarth
Yves Dutronc
Show All
Source
Cite
Save
Citations (3)
LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
2021
Journal of Investigative Dermatology
Brett A. King
O-Ki Kwon
Natasha Atanaskova Mesinkovska
Justin M. Ko
Yves Dutronc
W. Wu
Jill Shwed McCollam
GuangLei Yu
Katrin Holzwarth
Amy M. DeLozier
Maria K. Hordinsky
Show All
Source
Cite
Save
Citations (0)
The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.
2020
Journal of Biopharmaceutical Statistics
Gaohong Dong
Lu Mao
Bo Huang
Margaret Gamalo-Siebers
Jiuzhou Wang
GuangLei Yu
David C. Hoaglin
Show All
Source
Cite
Save
Citations (6)
1